Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Mayo Clinic
635 participants
Aug 1, 2018
OBSERVATIONAL
Conditions
Summary
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Eligibility
Inclusion Criteria2
- Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
- Patients willing to provide written informed consent
Exclusion Criteria1
- Unwillingness/unable to give blood samples
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03478826